Latest Protein-bound paclitaxel Stories
--$90 million+ up-front payment and $1.2 billion+ milestone payments SAN DIEGO, May 15, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc.
- Revenues increase 56 percent to $18.7 million, loss narrows to $15.1 million - SAN DIEGO, May 11, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc.
UPPSALA, Sweden, April 20, 2015 /PRNewswire/ -- Oasmia Pharmaceutical AB ("Oasmia") announced today that its lead cancer product Paclical received market authorization
Recent FDA meeting allows for potential marketing application based on progression free survival in pivotal Phase 3 pancreatic cancer study SAN DIEGO, April 8, 2015 /PRNewswire/ -- Halozyme
SAN DIEGO, Jan. 28, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 12, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc.
- ABRAXANE plus gemcitabine to be PBS listed for Australian patients with metastatic pancreatic cancer from 1 November MELBOURNE, Australia, Oct.
Urges provinces to move quickly to fund first new treatment for pancreatic cancer approved in Canada in 20 years HALIFAX, Sept.
High unmet need addressed with first new approved treatment in eighteen years MISSISSAUGA, ON, August 6, 2014 /CNW/ - Health Canada has approved (Pr)ABRAXANE(®)
SAN DIEGO, July 31, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) today announced the death of Mr.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.